Passive Aβ Immunotherapy: Current Achievements and Future Perspectives (Q60530538)

12 December 2020

Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease

1 reference

12 December 2020

Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice

1 reference

12 December 2020

Heterogeneity of water‐soluble amyloid β‐peptide in Alzheimer's disease and Down's syndrome brains

1 reference

12 December 2020

Isolation, Chemical Characterization, and Quantitation of Aβ 3-Pyroglutamyl Peptide from Neuritic Plaques and Vascular Amyloid Deposits

1 reference

12 December 2020

Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains

1 reference

12 December 2020

Presenilin-1 mutations in Alzheimer's disease.

1 reference

12 December 2020

Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

1 reference

12 December 2020

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

1 reference

12 December 2020

Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach

1 reference

12 December 2020

Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques

1 reference

12 December 2020

High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain

1 reference

12 December 2020

On the seeding and oligomerization of pGlu-amyloid peptides (in vitro)

1 reference

12 December 2020

Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation

1 reference

12 December 2020

Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology

1 reference

12 December 2020

Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides

1 reference

12 December 2020

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

1 reference

12 December 2020

1 reference

12 December 2020

The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide

1 reference

12 December 2020

Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process

1 reference

12 December 2020

The Development of New Therapeutics for Alzheimer's Disease

1 reference

12 December 2020

Alzheimer's failure raises questions about disease-modifying strategies

1 reference

12 December 2020

Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory

1 reference

12 December 2020

Extracellular phosphorylation of the amyloid β-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease

1 reference

12 December 2020

Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target

1 reference

12 December 2020

Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration.

1 reference

12 December 2020

1 reference

12 December 2020

Phosphorylation of amyloid beta (Aβ) peptides - a trigger for formation of toxic aggregates in Alzheimer's disease.

1 reference

12 December 2020

Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation

1 reference

12 December 2020

Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β

1 reference

12 December 2020

Pyroglutamate Amyloid-β (Aβ): A Hatchet Man in Alzheimer Disease

1 reference

12 December 2020

1 reference

12 December 2020

Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study

1 reference

12 December 2020

N-Terminal pyroglutamate formation of Aβ38 and Aβ40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation

1 reference

12 December 2020

Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-β.

1 reference

12 December 2020

Amyloid-β peptide: Dr. Jekyll or Mr. Hyde?

1 reference

12 December 2020

An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.

1 reference

12 December 2020

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

1 reference

12 December 2020

A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice

1 reference

12 December 2020

The global prevalence of dementia: a systematic review and metaanalysis

1 reference

12 December 2020

Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease

1 reference

12 December 2020

Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.

1 reference

12 December 2020

Alzheimer's Aβ42 and Aβ40 peptides form interlaced amyloid fibrils

1 reference

12 December 2020

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

1 reference

12 December 2020

Development and mechanism of γ-secretase modulators for Alzheimer's disease

1 reference

12 December 2020

Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier

1 reference

12 December 2020

Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models

1 reference

12 December 2020

Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease

1 reference

12 December 2020

Alzheimer disease therapy--moving from amyloid-β to tau.

1 reference

12 December 2020

Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle

1 reference

12 December 2020

Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease

1 reference

12 December 2020

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

1 reference

12 December 2020

Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review).

1 reference

12 December 2020

Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study

1 reference

12 December 2020

Advances in the management of macular degeneration

1 reference

12 December 2020

Truncated and modified amyloid-beta species

1 reference

12 December 2020

The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice

1 reference

12 December 2020

IgG subclasses and allotypes: from structure to effector functions

1 reference

12 December 2020

Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates

1 reference

12 December 2020

Improving drug delivery to primary and metastatic brain tumors: strategies to overcome the blood-brain barrier

1 reference

12 December 2020

Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies

1 reference

12 December 2020

The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis

1 reference

12 December 2020

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

1 reference

12 December 2020

Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed

1 reference

12 December 2020

Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies

1 reference

12 December 2020

An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice

1 reference

12 December 2020

Phosphorylation of the amyloid β-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity.

1 reference

12 December 2020

First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease

1 reference

12 December 2020

The amyloid hypothesis of Alzheimer's disease at 25 years

1 reference

12 December 2020

Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody

1 reference

12 December 2020

Evidence For and Against a Pathogenic Role of Reduced γ-Secretase Activity in Familial Alzheimer's Disease.

1 reference

12 December 2020

Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials

1 reference

12 December 2020

Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges

1 reference

12 December 2020

Recent global trends in the prevalence and incidence of dementia, and survival with dementia

1 reference

12 December 2020

A Greek Tragedy: The Growing Complexity of Alzheimer Amyloid Precursor Protein Proteolysis

1 reference

12 December 2020

Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies

1 reference

12 December 2020

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

1 reference

12 December 2020

The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model

1 reference

12 December 2020

Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice.

1 reference

12 December 2020

Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin

1 reference

12 December 2020

Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor.

1 reference

12 December 2020

Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy

1 reference

12 December 2020

APOE genotype and Alzheimer's immunotherapy.

1 reference

12 December 2020

AChE Inhibitors and NMDA Receptor Antagonists in Advanced Alzheimer's Disease

1 reference

12 December 2020

Fibril structure of amyloid-β(1-42) by cryo-electron microscopy

1 reference

12 December 2020

Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies

1 reference

12 December 2020

Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease

1 reference

12 December 2020

Alzheimer's disease drug development pipeline: 2017.

1 reference

12 December 2020

Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease

1 reference

12 December 2020

A Review of the Current Therapies, Challenges, and Future Directions of Transcranial Focused Ultrasound Technology: Advances in Diagnosis and Treatment

1 reference

12 December 2020

Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease

1 reference

12 December 2020

Modulation of mitochondrial bioenergetics as a therapeutic strategy in Alzheimer's disease

1 reference

12 December 2020

Safety and Efficacy of Scanning Ultrasound Treatment of Aged APP23 Mice.

1 reference

12 December 2020

Evaluating Potential QT Effects of JNJ-54861911, a BACE Inhibitor in Single- and Multiple-Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration-QTc Analysis.

1 reference

12 December 2020

Amyloid-β and Tau in Alzheimer's Disease: Novel Pathomechanisms and Non-Pharmacological Treatment Strategies

1 reference

12 December 2020